Results 41 to 50 of about 8,133 (230)

Phototherapy and photochemotherapy for polymorphic light eruption desensitisation:a five year case series review from a university teaching hospital [PDF]

open access: yes, 2017
Polymorphic light eruption (PLE) is the most common immunological photodermatosis, with a prevalence of 18% in Europe1. The pathogenesis of PLE appears to involve delayed cell mediated hypersensitivity and aberrant Langerhans cell function2,3 ...
Bilsland   +7 more
core   +2 more sources

PUVA therapy for photosensitive psoriasis

open access: yesActa Dermato-Venereologica, 1987
The purpose of this study was to assess the prophylactic effect of oral photochemotherapy with psoralens and UVA (PUVA) on patients with light-sensitive psoriasis. Of fifteen patients with photosensitive psoriasis, ten with a history of polymorphous light eruption (PMLE) slowly developing into psoriasis were treated with trimethylpsoralen (TMP) and UVA.
A M, Ros, G, Wennersten
openaire   +2 more sources

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won   +11 more
wiley   +1 more source

The PARP inhibitor PJ-34 sensitizes cells to UVA-induced phototoxicity by a PARP independent mechanism [PDF]

open access: yes, 2016
K
Hegedűs, Csaba   +6 more
core   +1 more source

Assessment of Treatment Response in Patients With Scleromyxedema by the Double Modified Rodnan Skin Score

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Scleromyxedema (SMX) is a cutaneous mucinosis characterised by an abnormal accumulation of mucin in the skin and limited treatment options. Assessment of therapy response during treatment is challenging. Objectives Patients with SMX receiving high‐dose intravenous IVIg therapy were included to assess validity of the double modified ...
Julia K. Winkler, Alexander H. Enk
wiley   +1 more source

Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis.

open access: yesPLoS ONE, 2014
Photo-activation of psoralen with UVA irradiation, referred to as PUVA, is used in the treatment of proliferative skin disorders. The anti-proliferative effects of PUVA have been largely attributed to psoralen intercalation of DNA, which upon UV ...
Wenle Xia   +8 more
doaj   +1 more source

Juvenile Mycosis Fungoides: A Multicenter Retrospective Italian Study

open access: yesJEADV Clinical Practice, EarlyView.
This multicenter retrospective study included 29 juvenile mycosis fungoides (JMF) patients from five Italian centres with confirmed histopathological diagnosis. most often presents with hypopigmented/classic variants and CD8+ phenotype. Early‐onset cases ( < 14 years) show better long‐term outcomes.
Andrea Michelerio   +8 more
wiley   +1 more source

Dermoscopic changes of melanocytic nevi after psoralen-ultraviolet a and narrow-band ultraviolet B phototherapy

open access: yesIndian Journal of Dermatology, 2016
Background: Phototherapy may alter the morphologic features of melanocytic nevi. Dermoscopy is a non-invasive method for evaluation of skin lesions, specifically melanocytic nevi.
Hayedeh Ghani-Nejad   +6 more
doaj   +1 more source

Brentuximab Vedotin‐Induced Rash Sparing CD30‐Positive Mycosis Fungoides Lesions

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Brentuximab vedotin (BV) is an effective treatment for CD30‐positive lymphomas, including mycosis fungoides (MF). However, its use can be associated with various cutaneous adverse effects, including rashes. This case describes a 60‐year‐old male with stage IIB MF who developed a drug‐induced erythematous rash after three infusions of BV ...
Isabel Hariri   +2 more
wiley   +1 more source

Dynamics of expression rates of growth factor proteins in psoriatic patients receiving a phototherapy

open access: yesVestnik Dermatologii i Venerologii, 2017
Goal. To study the dynamics of expression rates of growth factor proteins in psoriatic patients receiving the PUVA therapy. Materials and methods. The authors conducted a study of 30 patients with psoriasis vulgaris treated with the PUVA therapy.
V. V. Chikin   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy